https://www.selleckchem.com/pr....oducts/CP-690550.htm
Animal models implicate FGF-23 (fibroblast growth factor-23) as a direct contributor to adverse cardiorenal interactions such as sodium avidity, diuretic resistance, and neurohormonal activation, but this has not been conclusively demonstrated in humans. Therefore, we aimed to evaluate whether FGF-23 is associated with parameters of cardiorenal dysfunction in humans with heart failure, independent of confounding factors. One hundred ninety-nine outpatients with heart failure undergoing diuretic treatment at the Yale Transitional Care
Like
Comment
Share
